Media
Date
Title
28 June
16 March
15 March
QBiotics concludes successful $85 million capital raise
FNArena.com
TDM ploughs $50m into anti-cancer biotech QBiotics
Financial Review (PDF)
QBiotics joins TDM Growth Partners to accelerate drug development timelines
BioSpectrum Asia
30 November
29 November
22 November
19 November
19 November
18 November
16 November
20 August
19 August
14 August
13 August
22 July
22 June
22 June
17 June
30 April
15 March
21 January
20 January
10 January
Virbac Teams With QBiotics On Cancer Product
Today's Veterinary Business
Biotech Stocks Facing FDA Decision In December 2020
Markets Insider
New Drug to Treat Some Mast Cell Tumors in Dogs
Steve Dale Pet World
FDA approval for QBiotics' canine cancer treatment
Biotech Dispatch
FDA Approves QBiotics’ Veterinary Anti-Cancer Treatment Stelfonta
Pet Insight
QBiotics' STELFONTA Receives FDA Approval for Canine Mast cell Tumours
BioSpace.com
FDA Approves First Intratumoral Injection to Treat Non-Metastatic Mast Cell Tumors in Dogs
U.S. Food and Drug Administration
QBiotics announces clinical collaboration with MSD targeting unresectable melanoma
Select Science
QBiotics Group Limited collaborates with MSD
Pharma Tech Outlook
QBiotics announces clinical collaboration with MSD targeting unresectable melanoma
Oncology News
QBiotics in new cancer collaboration with MSD
Biotech Dispatch
QBiotics Doses 1st Australian head, neck cancer patient
Biotech Daily
New canine cancer treatment available
Vet Practice Magazine
New cancer treatment available for dogs
Get Stem.com
Promising New Cancer Treatment for Dogs with Mast Cell Tumours
Australian Dog Lover
QBiotics commercialises first tigilanol tiglate pharmaceutical product
Biotech Dispatch
Dr Boreham’s Crucible: Why unlisted QBiotics has a good chance of cracking the cancer market
Stockhead.com
European approval for QBiotics tigilanol tiglate
Biotech Dispatch
QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of STELFONTA
Medianet
Anticancer candidate trialled in solid tumours
Lab Online
12 December
10 December
9 December
6 December
QBiotics Announces First Patient Dosed in its Phase I/II Clinical Trial of Tigilanol Tiglate for Head and Neck Cancer
BioSpace.com
QBiotics updates on publication of tigilanol tiglate trial results
Biotech Dispatch
Publication of First In-Human Data Reveals Safety & Efficacy of Tigilanol Tiglate in Solid Tumours
BioSpace.com
Rudi’s View: Osteopore, Whitehaven Coal and Telstra
FNArena.com